← Leaderboards
David R Archer
Emory University
$6,339,785
Attributed
$9,098,845
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,098,845 · 8
By mechanism
R01$7,025,880 · 4
R33$1,033,503 · 1
R61$547,199 · 1
R21$275,991 · 1
R29$216,272 · 1
Top collaborators
- Kenneth I Ataga5 shared
- William Robert Taylor4 shared
- Antonio Guasch3 shared
Most similar at Emory University
Same institution · by research overlap
- Wilbur A Lam$39,688,140
- Clinton H. Joiner$9,117,959
- Antonio Guasch$2,151,714
- Peter A Lane$654,618
- Jens Peter Wrammert$5,852,233
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaSickle CellKidney FailureLeadHemolysisBaseResponseHemoglobinMouse ModelBone Marrow TransplantationBloodLaboratory MouseKidneyKidney DiseasesReportingAlbuminuriaAlbuminsExcretory FunctionCreatininePathogenesisRegulationExhibitsFunctional DisorderMicroalbuminuria
Grant awards (24)
Small Molecule Therapeutics for Sickle Cell Anemia$543,950
R33 · FY2025 · HL · contact PI
Small Molecule Therapeutics for Sickle Cell Anemia$489,553
R33 · FY2024 · HL · contact PI
Small Molecule Therapeutics for Sickle Cell Anemia$547,199
R61 · FY2023 · HL · contact PI
Impaired Collateral Vessel Formation in Sickle Cell Disease$605,307
R01 · FY2019 · HL
Impaired Collateral Vessel Formation in Sickle Cell Disease$605,307
R01 · FY2018 · HL
Impaired Collateral Vessel Formation in Sickle Cell Disease$605,307
R01 · FY2017 · HL
Impaired Collateral Vessel Formation in Sickle Cell Disease$605,307
R01 · FY2016 · HL
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$474,581
R01 · FY2016 · HL
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$450,727
R01 · FY2015 · HL
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$450,555
R01 · FY2014 · HL
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$438,932
R01 · FY2013 · HL
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$504,596
R01 · FY2012 · HL
The Pathogenesis of Sickle Cell Nephropathy$350,001
R01 · FY2010 · DK · contact PI
The Pathogenesis of Sickle Cell Nephropathy$77,500
R01 · FY2010 · DK · contact PI
The Pathogenesis of Sickle Cell Nephropathy$350,001
R01 · FY2009 · DK · contact PI
Allogeneic chimerism in murine sickle cell disease$359,266
R01 · FY2006 · HL · contact PI
Allogeneic chimerism in murine sickle cell disease$387,007
R01 · FY2005 · HL
Allogeneic chimerism in murine sickle cell disease$18,743
R01 · FY2005 · HL
Allogeneic chimerism in murine sickle cell disease$370,543
R01 · FY2004 · HL
Allogeneic chimerism in murine sickle cell disease$372,200
R01 · FY2003 · HL
Functional Analysis of Hematopoietic Stem Cell Origin$131,156
R21 · FY2002 · DK
Functional Analysis of Hematopoietic Stem Cell Origin$144,835
R21 · FY2001 · DK
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA$108,136
R29 · FY2001 · HL
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA$108,136
R29 · FY2000 · HL